TY - JOUR
T1 - Safety of Bisphosphonates in the Treatment of Osteoporosis
AU - Recker, Robert R.
AU - Lewiecki, E. Michael
AU - Miller, Paul D.
AU - Reiffel, James
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009
Y1 - 2009
N2 - In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).
AB - In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).
UR - http://www.scopus.com/inward/record.url?scp=58949086108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58949086108&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2008.12.004
DO - 10.1016/j.amjmed.2008.12.004
M3 - Article
C2 - 19187809
AN - SCOPUS:58949086108
VL - 122
SP - S22-S32
JO - American Journal of Medicine
JF - American Journal of Medicine
SN - 0002-9343
IS - 2 SUPPL.
ER -